USAdvisors Wealth Management LLC Purchases New Shares in Aquestive Therapeutics, Inc. $AQST

USAdvisors Wealth Management LLC purchased a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $33,000.

A number of other institutional investors have also recently modified their holdings of AQST. Millennium Management LLC lifted its position in shares of Aquestive Therapeutics by 111.2% during the 4th quarter. Millennium Management LLC now owns 87,227 shares of the company’s stock valued at $311,000 after acquiring an additional 45,926 shares during the period. Two Sigma Investments LP lifted its position in shares of Aquestive Therapeutics by 31.5% during the 4th quarter. Two Sigma Investments LP now owns 175,952 shares of the company’s stock valued at $626,000 after acquiring an additional 42,160 shares during the period. Two Sigma Advisers LP bought a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at $57,000. Trust Point Inc. lifted its position in shares of Aquestive Therapeutics by 69.9% during the 1st quarter. Trust Point Inc. now owns 23,396 shares of the company’s stock valued at $68,000 after acquiring an additional 9,625 shares during the period. Finally, Janney Montgomery Scott LLC lifted its position in shares of Aquestive Therapeutics by 7.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company’s stock valued at $3,073,000 after acquiring an additional 75,275 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on AQST shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Saturday, September 27th. Zacks Research upgraded Aquestive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 13th. Lifesci Capital raised Aquestive Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Oppenheimer boosted their price target on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Monday, September 8th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.29.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $5.80 on Friday. Aquestive Therapeutics, Inc. has a one year low of $2.12 and a one year high of $6.43. The stock’s 50-day moving average is $4.53 and its 200 day moving average is $3.60. The firm has a market cap of $578.38 million, a price-to-earnings ratio of -8.29 and a beta of 1.77.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Insider Activity at Aquestive Therapeutics

In related news, insider Peter E. Boyd sold 10,000 shares of the company’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $6.30, for a total transaction of $63,000.00. Following the sale, the insider owned 278,323 shares in the company, valued at $1,753,434.90. This represents a 3.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Barber sold 91,343 shares of the company’s stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $6.03, for a total value of $550,798.29. Following the sale, the chief executive officer owned 923,430 shares in the company, valued at approximately $5,568,282.90. The trade was a 9.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 178,923 shares of company stock worth $1,006,598 in the last 90 days. Corporate insiders own 8.35% of the company’s stock.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.